Alpha-1 antitrypsin deficiency (AATD) is a genetic disorder that leads to an increased risk for liver and lung disease. Although more than 100,000 people in the United States have AATD, fewer than 10% of them have been diagnosed. Additionally, in those who are diagnosed, the diagnosis is delayed on average by 5.6 years. Unfortunately, the availabilty of evidence-based recommendations from the American Thoracic Society and The European Respiratory Society has done little to raise awareness about the diagnosis and management of this important condition.
This activity is designed to engage your critical thinking about patients who may have AATD and to challenge suboptimal approaches to the management of patients with AATD lung disease. You will hear unique insights from 3 clinical experts and a patient living with AATD during this dynamic presentation.